Clearside Biomedical : January 2021 Corporate Presentation 30.2 MB
January 12, 2021 at 08:08 am
Share
Corporate Presentation | January 2021
Forward-Looking Statements
This presenta+on contains forward-looking statements as defined in the Private Securi+es Li+ga+on Reform Act of 1995, as amended. The words "may," "will," "could," "would," "should," "expect," "plan," "an+cipate," "intend," "believe," "es+mate," "predict," "project," "poten+al," "con+nue," "target" and similar expressions are intended to iden+fy forward-looking statements, although not all forward- looking statements contain these iden+fying words. Clearside Biomedical, Inc.'s views as of the date of this presenta+on about future events and are subject to risks, uncertain+es, assump+ons, and changes in circumstances that may cause Clearside's actual results, performance, or achievements to differ significantly from those expressed or implied in any forward-looking statement. Although Clearside believes that the expecta+ons reflected in the forward-looking statements are reasonable, Clearside cannot guarantee future events, results, performance, or achievements. Some of the key factors that could cause actual results to differ from Clearside's expecta+ons include its plans to develop and poten+ally commercialize its product candidates; Clearside's planned clinical trials and preclinical studies for its product candidates; the +ming of and Clearside's ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials poten+ally required for Clearside's product candidates; the clinical u+lity and market acceptance of Clearside's product candidates; Clearside's commercializa+on, marke+ng and manufacturing capabili+es and strategy; Clearside's intellectual property posi+on; and Clearside's ability to iden+fy addi+onal product candidates with significant commercial poten+al that are consistent with its commercial objec+ves. For further informa+on regarding these risks, uncertain+es and other factors you should read the "Risk Factors" sec+on of Clearside's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 13, 2020, Clearside's Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed with the SEC on November 10, 2020, and Clearside's other Periodic Reports filed with the SEC. Clearside expressly disclaims any obliga+on to update or revise the informa+on herein, including the forward-looking statements, except as required by law. This presenta+on also contains es+mates and other sta+s+cal data made by independent par+es and by Clearside rela+ng to market size and growth and other data about its industry. This data involves a number of assump+ons and limita+ons, and you are cau+oned not to give undue weight to such es+mates. In addi+on, projec+ons, assump+ons and es+mates of Clearside's future performance and the future performance of the markets in which Clearside operates are necessarily subject to a high degree of uncertainty and risk.
2
2
Developing and Delivering Treatments that Restore and Preserve
Vision for People with Serious Back of the Eye Diseases
Versatile Therapeutic Platform
SCS Microinjector® with proprietary
drug formulations target the
Suprachoroidal Space
Proprietary Access to the Suprachoroidal Space (SCS®)
U?liza?on Across Small Molecules and Gene Therapy
Ability to Target Mul?ple Ocular Diseases
Internal Research & Development Pipeline
External Collaborations for Pipeline Expansion
3
3
Evolution of Injection Procedures to Reach the Back of the Eye
Periocular Injection
Highly variable drug diffusion across the sclera into the eye
Intravitreal Injec-on
Broad diffusion to all areas of the eye including the anterior chamber and lens
Subretinal Injection
Invasive surgery with variable results
Suprachoroidal Space Injection
Novel SCS Microinjector® allows for precise
delivery into the suprachoroidal space
4
4
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
Clearside Biomedical Inc. published this content on 12 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 January 2021 13:07:08 UTC
Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.